Therapeutic areas: Oncology, Cardiovascular
Novartis cardiovascular reps have navigated significant restructuring as Entresto approaches its patent cliff and Leqvio (inclisiran) faces slower-than-expected infusion adoption. Oncology reps benefit from Kisqali, Lutathera, and a growing radioligand therapy pipeline. The company has been restructuring its U.S. commercial model across multiple waves.
Key products: Entresto, Kisqali, Leqvio, Cosentyx, Kesimpta
Novartis cardiovascular reps have navigated significant restructuring as Entresto approaches its patent cliff and Leqvio (inclisiran) faces slower-than-expected infusion adoption. Oncology reps benefi